Compare SCVL & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCVL | XFOR |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 407.5M |
| IPO Year | 1994 | N/A |
| Metric | SCVL | XFOR |
|---|---|---|
| Price | $17.20 | $4.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 418.7K | 376.8K |
| Earning Date | 05-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,135,324,000.00 | N/A |
| Revenue This Year | $1.64 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.04 | $1.35 |
| 52 Week High | $26.54 | $4.83 |
| Indicator | SCVL | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 53.21 |
| Support Level | $16.80 | $3.57 |
| Resistance Level | $18.37 | $4.57 |
| Average True Range (ATR) | 0.72 | 0.23 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 12.14 | 37.68 |
Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual, and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs. The company operates its business as one reportable segment based on the similar nature of products sold; merchandising, distribution, and marketing processes involved; target customers; and economic characteristics of stores and e-commerce platforms. Its bricks-first, omnichannel approach provides customers easy access to a wide assortment of branded footwear for work, athletics, daily activities, and special events via a choice of delivery channels.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.